This is the second article in LuTra Studio’s ADC series, written for readers without prior ADC expertise who want to understand ADC evolution—specifically, why antibody–drug conjugates experienced widespread failures in the 2000s but emerged as one of the most important oncology platforms after 2020. Rather than starting with definitions, this article traces the historical failures, engineering corrections, and strategic shifts that shaped modern ADC development across differ

Introduction | AI in Pharmaceutical Drug Development The pharmaceutical industry is undergoing a profound shift as AI in pharmaceutical drug development and digital transformation reshape how modern medicines are discovered, tested, manufactured, and delivered. In Part I of this series, we explored the essential functions inside pharma companies. In Part II, we examined how drugs navigate the regulatory approval process, market access, and post-market surveillance. In this t

The pharmaceutical industry is more than just lab coats and experiments — it’s a complex ecosystem where science, engineering, and business intersect. From R&D and manufacturing to clinical trials, regulatory affairs, and business development, each department plays a critical role in transforming a molecule into a life-changing medicine. Explore how these teams work together to bring innovation from the lab to the patient.